Background: The HeartMate 3 (HM3; Abbott Laboratories, Lake Forest, Ill) left ventricular assist device (LVAD) received its Conformit e Europ eenne mark for Europe in October 2015 and is currently under investigation of the Food and Drug Administration to gain approval in the United States. Within this study, we present the first real-world experiences, 1-year outcomes, and adverse events of a single-center cohort treated with the HM3.
In the European CE mark study, 2, 4, 5 as well in the US-based Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) trial, 3 the HM3 presented a low adverse event profile for pump thrombosis as well as reoperation and showed excellent outcomes. Yet, real-world experience outside the study setting is rare. 6, 7 The Hannover group previously reported 6-month results and adverse events of therapy with the HM3 in a post-CE mark cohort. 6 In this study, we now follow up on this cohort and present 1-year outcomes and complications of a single-center cohort after HM3 implantation.
METHODS Patients
We prospectively studied a patient cohort of 27 patients who were supported with the continuous-flow left ventricular assist device (LVAD) Heartmate 3 at a single institution between June 2014 and April 2017. Of the study cohort, 8 patients were part of the HM3 CE mark trial in 2014, including the first in-human patient as of June 25, 2014. 1 For the performance of this prospective study, the database of Hannover Medical School, Hannover, Germany, was used. All causes of death and adverse events were determined through examination of medical records. Only primary implantations were included in this study. Exclusion criteria were biventricular assist devices and other types of assist devices as well as LVAD exchange and reoperative procedures. All patients underwent HM3 implantation via full sternotomy via conventional technique with outflow graft anastomosis to the ascending aorta. No concomitant procedures were performed. Heparin was started 6 hours after surgery. Intravenous heparin was administered as a bridge until anticoagulation with phenprocoumon was in the therapeutic range, with a target international normalized ratio (INR) of 2.0 to 3.0, plus aspirin at 100 mg/d. Blood pressure was measured by Doppler sonography in all patients. Target blood pressure was 60 to 65 mm Hg (mean). 6 
Study Design
The data were prospectively collected by electronic medical record review. Baseline characteristics were obtained for all patients before HM3 implantation. After HM3 implantation, survival, causes of death, and complications were recorded for all patients. Follow-up was 100% complete. Minimal follow-up time was 12 months; maximal follow-up time was 28 months. The hospital ethical review board waived the need for patient consent to this study. Preoperatively, 1 patient in the study cohort was supported by Impella (ABIOMED, Inc, Danvers, Mass) due to a fulminant myocardial infarction. No patients were preoperatively supported by extracorporeal membrane oxygenation or intra-aortic balloon pump. The most common preoperative risk factor was pulmonary hypertension (pulmonary artery pressure mean greater than 25 mm Hg) (22.4%). Four (4/27, 14.8%) patients were diagnosed with type II diabetes. Four (4/27, 14.8%) patients had a myocardial infarction within the last 90 days before LVAD implantation. None of the patients underwent previous cardiac surgery. 6 Outcomes After HM3 Implantation
Statistical Methods
The Kaplan-Meier curve in Figure 1 illustrates the patient survival. Fifteen days after HM3 implantation, a survival of 96.3% (26/27) was observed in the study cohort. After 30 days, the survival rate was 89%, 89% after 3 months, 85% 6 months, and 85% 1 year after HM3 implantation.
Of 27 patients, after a timespan of 1 year, 2 patients (2/27, 7.4%) had successfully undergone heart transplantation on postoperative day (POD) 51 and 337; 22 patients are still ongoing on the device. The longest ongoing patient out of the HM3 study is on device for more than 2.5 years as of April 1, 2017.
Causes of Death
One year after HM3 implantation, of 27 patients, 3 patients died. All deceased patients died in the early postoperative course. The first patient died on POD 17 due to pneumonic sepsis. The second and the third patient died on POD 7 and POD 22 due to multiorgan failure including right heart failure.
Complications 1 Year After HM3 Implantation
Adverse events are listed in Table 2 . A total of 12 bleeding events were observed in 8 patients of the study group (8/27, 29.6%). Of those, one was a gastrointestinal bleeding event (3.7%, 0.0428583 events per patient year [ppy]) and one a late tamponade that required rethoracotomy (3.7%, 0.0428583 events ppy).
No case of pump thrombosis or pump dysfunction was recorded in the cohort. No case of either hemorrhagic or embolic stroke was observed in the study group. FIGURE 1. Kaplan-Meyer survival curves presenting the survival of the study group one year after HeartMate 3 implantation. Time to death was modeled using Kaplan-Meier curves and 95% confidence limits. Participants were censored when the device was explanted or in case of cardiac transplantation.
Two patients were diagnosed with coagulations disorder (7.4%). Both cases were classified as von-Willebrand factor deficiency.
Infection remained the major complication 1 year after HM3 implantation, with 8 LVAD-related events in 6 patients (22.2%, 0.3428839 events ppy). Seven patients presented with 9 events of non-LVAD-related infections (25.9%, 0.3857429 events ppy).
Right heart failure was diagnosed in 2 patients (2/27, 7.4%, 0.0857202 events ppy) in the early postoperative course. Both patients died in the first month after HM3 implantation.
Pre-and Postoperative Organ Function
Pre-and postoperative laboratory values are presented in Figure 2 . Liver parameters alanine transaminase (U/L) and 
Lactate Dehydrogenase (LDH) and Free Hemoglobin
The average LDH (U/L) as well as free hemoglobin (mg/L) laboratory values are displayed in Figure 3 . The free hemoglobin curve shows a steep decline, followed by a slight increase in the sixth postoperative month and declines again until 1 year after implantation to 91 AE 56.1 mg/L. LDH levels showed a decrease during the entire study period and reached a steady level of mean 262.7 AE 56.5 U/L at 1 year after implantation.
LVAD Parameters After HM3 Implantation
LVAD parameters after implantation are depicted in Table 3 . One month after implantation the average speed was 5365 RPM, after 6 months 5552 RPM, and after 12 months 5581 RPM. Mean power was 3.77 W after 1 month, 4.33 W after 6 months, and 4.30 W after 12 months of LVAD support.
DISCUSSION
The European CE Mark trial 1,2,4,5 as well as the US-based MOMENTUM 3 data 3 already showed excellent short-to-midterm results for HM3. The HM3 CE Mark trial showed a 6-month survival of 92%, and the MOMENTUM 3 trial showed a 6-month survival of 86.2% in the study group. 2, 3 We previously reported a 6-month outcome of 85% of the presented cohort, 6 without any additional deaths. The 1-year outcome of our cohort remained at 85%.
Real-world experience of therapy with the HM3 is rare (Table 4 ). Ozturk and colleagues 7 presented their short-term results of 8 patients who received HM3. The data show that HM3 implantation in their institution is associated with decreased bleeding complications and blood product administration as well as shorter implantation times compared with patients who received HMII.
Recently, the 1-year results of the HM3 CE mark study have been published. 5 One-year survival was 74%, with 6% cardiac transplantations and 2% explantations due to cardiac recovery. Main complications of the study group were 12% gastrointestinal bleeding, 16% driveline infections, and 18% strokes. Again, no pump thrombosis or malfunctions were observed in the study cohort. 5 So far, in the 1-year follow-up, no pump thrombosis was observed in our patient cohort. In accordance with our results, the CE Mark Study as well as the MOMENTUM trial also reported no pump thrombosis respectively. [1] [2] [3] [4] [5] Debilitating strokes were reported in 7.9% of the patients in the MOMENTUM trial 3 and in 18% of the patients in the 1-year follow-up of the CE mark study 5 In our patient population, also 1 year after HM3 implantation, no strokes were observed.
According to study protocols, anticoagulation of HM3 was in the therapeutic range, with a target INR of 2.0 to 3.0, plus aspirin at 100 mg/d. One gastrointestinal bleeding was observed (3.7%). The 1-year CE Mark and the 6 months MOMENTUM 3 data indicate rates of 12% and 11.9%, respectively.
3,5 Hemocompatibility of the HM3 was investigated in a secondary analysis of the MOMENTUM 3 data by Uriel and colleagues 8 to evaluate the aggregate of hemocompatibility-related clinical adverse events. This subanalysis also demonstrated a reduced adverse event profile for the HM3 compared with the HMII.
Consecutively, because of the trend for a low rate of pump thrombosis throughout the currently published studies on HM3, it should be assessed whether a reduction of anticoagulation is possible with the new device, eg, lowering the risk of gastrointestinal bleedings.
Anticoagulation is a major factor in preventing pump thrombosis. Yet, too-strict regimens increase the risk of bleeding complications such as gastrointestinal bleeding or hemorrhagic stroke. The Study of Reduced Anti-Coagulation/Anti-Platelet Therapy in Patients With the HeartMate II LVAS (TRACE) study questioned the need of double anticoagulation in patients with HMII to reduce the risk of pump thrombosis. The 1-year results revealed that reducing antithrombotic therapies in response to bleeding among patients with HMII was achievable but may be associated with a greater risk for device thrombosis. 9 However, the recently published 2-year results showed that managing patients undergoing HMII with a vitamin K antagonist with a target INR of 2.3 without antiplatelet therapy may help to reduce the incidence of major bleeding without increasing the risk of thromboembolic events, including ischemic stroke and pump thrombosis. 10 Consequently, a multicenter trial with a reduction of anticoagulation for the HM3 should be discussed.
High-pump speeds !9000 RPMs for the HMII are associated with a lower risk for pump thrombosis. 11 A total of 15 patients who received HM3 underwent ramp study testing with right heart catheterization including central venous pressure, pulmonary artery pressure, pulmonary capillary wedge pressure, blood pressure, and 3-dimensional echocardiography 12 6 months after HM3 implantation. LVAD RPMs (rotations per minute) were set to achieve normal wedge as well as central venous pressures to result in improved physiologic flow in the circulatory system. According to the authors, hemodynamic normalization of pressures was achieved in the majority of patients implanted with the HM3 pump within a narrow speed range. 12 Careful re-evaluation of HM3 pump settings should therefore be regularly performed to achieve best results. Surgical pump exchange is a possible treatment option for pump thrombosis. Because of the significant reduction in the rate of pump thrombosis compared with the HMII, a device upgrade to HM3 should be discussed as a treatment option. Other reported adverse events of the MOMENTUM 3 as well the CE mark trial were observed in similar rates in our study population. In summary, device-related infections and bleeding complications remain major challenges in patients with LVADs and prevention is of upmost importance (Video 1). 13 
Limitations
This study has several limitations. All implantations were performed at a single center and therefore reproducibility may be limited and is affected by institutional experience. The results of surgical studies are prone to learning curves and a single center's specific characteristics. Moreover, the study period began 3 years ago. Therapeutic strategies and increased clinical experience might improve today's results.
In addition, the number of patients on the new device was small, which in turn reduces the precision of our estimates. This is reflected for example, by the wide confidence intervals in the Kaplan-Meier curve. Therefore, the small sample size of the cohort limits the precision of the results of this study. As such, large-sample, real-world studies on the outcomes of patients with HM3 need to be performed. Furthermore, this study is limited to a single left ventricular assist device and does not compare the outcomes of other comparable assist devices. Larger, prospective, randomized controlled studies are worthwhile to compare the long-term outcomes of different types of assist devices.
CONCLUSIONS
The novel LVAD HM3 has already shown excellent CE mark trial results. After 1 year of therapy, the survival in our study group is 85%. The HM3 continued to show a low adverse event rate profile without stroke and pump thrombosis one year after implantation.
